Sunday, June 14, 2015 6:20:35 PM
On May 28, 2015, the Company received a warning letter dated May 27, 2015 (the “Warning Letter”), from the U.S. Food and Drug Administration (the “FDA”) resulting from an inspection of the Company’s facility in River Edge, New Jersey by the FDA’s New Jersey District Office that occurred during October 2014. The Warning Letter alleges deficiencies relating to the Company’s compliance with the Quality System regulation and the Medical Device Reporting regulation. The Company takes the matters identified in the Warning Letter seriously and is in the process of evaluating the corrective actions required to address the matters raised in the Warning Letter. The Company also is in the process of preparing a response to the Warning Letter and intends to respond fully to the issues raised by the FDA within 15 business days as requested by the FDA, and to work diligently and expeditiously to resolve the issues raised by the FDA. The Warning Letter does not restrict the manufacture, production or shipment of any of the Company’s products, nor require the withdrawal of any product from the marketplace. However, failure to promptly address the issues raised in the Warning Letter to the FDA’s satisfaction or to comply with U.S. medical device regulatory requirements in general could result in regulatory action being initiated by the FDA. These actions could include, among other things, delays in approval of any FDA applications, product seizures, injunctions and civil monetary penalties. Any such actions could disrupt our ongoing business and operations and potentially have a material adverse impact on our financial condition and operating results. A copy of the Warning Letter is attached hereto as Exhibit 99.1.
Everything I say and write is my opinion and my opinion only. Do your own due diligence when investing
Recent NEPH News
- Nephros Announces Fourth Quarter and Fiscal Year 2023 Financial Results • GlobeNewswire Inc. • 03/07/2024 09:15:00 PM
- Nephros Schedules Conference Call for Fourth Quarter and Fiscal Year 2023 Financial Results • GlobeNewswire Inc. • 02/29/2024 09:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:48:48 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:48:32 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:48:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/11/2023 09:17:43 PM
- Nephros Announces Results for Quarter Ended September 30, 2023 • GlobeNewswire Inc. • 11/08/2023 09:15:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/08/2023 09:00:48 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/06/2023 09:05:37 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/03/2023 08:30:14 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 11/03/2023 08:29:28 PM
- Nephros Hires Judy Krandel as Chief Financial Officer • GlobeNewswire Inc. • 11/01/2023 11:30:00 AM
- Nephros Schedules Third Quarter 2023 Financial Results Conference Call • GlobeNewswire Inc. • 10/25/2023 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/15/2023 08:15:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/09/2023 08:15:27 PM
- Nephros Announces Results for Quarter Ended June 30, 2023 • GlobeNewswire Inc. • 08/09/2023 08:15:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2023 08:00:51 PM
- Nephros Schedules Second Quarter 2023 Financial Results Conference Call • GlobeNewswire Inc. • 07/26/2023 11:30:00 AM
- Nephros Announces Results for Quarter Ended March 31, 2023 • GlobeNewswire Inc. • 05/10/2023 08:15:00 PM
- Nephros Announces CEO Retirement and Succession Plan • GlobeNewswire Inc. • 05/08/2023 11:30:00 AM
FEATURED Cannabix's Breath Logix Alcohol Device Delivers Positive Impact to Private Monitoring Agency in Montana, USA • Apr 25, 2024 8:52 AM
Bantec Reports an Over 50 Percent Increase in Sales and Profits in Q1 2024 from Q1 2023 • BANT • Apr 25, 2024 10:00 AM
Kona Gold Beverages, Inc. Announces Name Change to NuVibe, Inc. and Initiation of Ticker Symbol Application Process • KGKG • Apr 25, 2024 8:30 AM
Axis Technologies Group and Carbonis Forge Ahead with New Digital Carbon Credit Technology • AXTG • Apr 24, 2024 3:00 AM
North Bay Resources Announces Successful Equipment Test at Bishop Gold Mill, Inyo County, California • NBRI • Apr 23, 2024 9:41 AM
Epazz, Inc.: CryObo, Inc. solar Bitcoin operations will issue tokens • EPAZ • Apr 23, 2024 9:20 AM